<html>
  <head>
    <title></title>
    <!-- Licensed to: Sabres09!
         Document created using EDGARfilings PROfile 7.0.0.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-size: 14pt; font-weight: bold;">UNITED STATES</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-size: 12pt; font-weight: bold;">WASHINGTON, DC 20549</div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      <div><br>
      </div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-size: 18pt; font-weight: bold;">FORM 8-K</div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      <div style="text-align: center; color: #000000; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; color: #000000; font-weight: bold;">CURRENT REPORT</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">Pursuant to Section 13 or 15(d) of the</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">Securities Exchange Act of 1934</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">Date of Report (Date of earliest event reported): May 13, 2020</div>
      <div style="text-align: center; color: #000000; font-weight: bold;"> <br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
        <div> <br>
        </div>
      </div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-size: 24pt; font-weight: bold;">PDS BIOTECHNOLOGY CORPORATION</div>
      <div style="text-align: center; color: #000000; font-weight: bold;">(Exact Name of Registrant as Specified in Charter)</div>
      <div style="color: rgb(0, 0, 0); font-weight: bold;"> <br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      <table cellspacing="0" cellpadding="0" border="0" id="z4cd072e171da4d44bf9321884b7a1803" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 33.01%; vertical-align: top; background-color: rgb(255, 255, 255);">
              <div style="text-align: center; color: rgb(0, 0, 0);"><u>Delaware</u></div>
            </td>
            <td style="width: 33.99%; vertical-align: top; background-color: rgb(255, 255, 255);">
              <div style="text-align: center; color: rgb(0, 0, 0);"><u>001-37568</u></div>
            </td>
            <td style="width: 32.99%; vertical-align: top; background-color: rgb(255, 255, 255);">
              <div style="text-align: center; color: rgb(0, 0, 0);"><u>26-4231384</u></div>
            </td>
          </tr>
          <tr>
            <td style="width: 33.01%; vertical-align: top; background-color: rgb(255, 255, 255);">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(State or Other Jurisdiction of Incorporation)</div>
            </td>
            <td style="width: 33.99%; vertical-align: top; background-color: rgb(255, 255, 255);">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(Commission File Number)</div>
            </td>
            <td style="width: 32.99%; vertical-align: top; background-color: rgb(255, 255, 255);">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">(I.R.S. Employer Identification No.)</div>
            </td>
          </tr>

      </table>
      <div style="text-align: center; color: #000000; font-weight: bold;"><u> <br>
        </u></div>
      <div style="text-align: center; color: #000000; font-weight: bold;"><u>25B Vreeland Road</u></div>
      <div style="text-align: center; color: #000000; font-weight: bold;"><u>Florham Park NJ 07932</u></div>
      <div style="text-align: center; color: #000000; font-weight: bold;">&#160;(Address of Principal Executive Offices, and Zip Code)</div>
      <div><br>
      </div>
      <div style="text-align: center; color: #000000;"><u>(800) 208-3343</u></div>
      <div style="text-align: center; color: #000000; font-weight: bold;">Registrant&#8217;s Telephone Number, Including Area Code</div>
      <div style="text-align: center; color: #000000; font-weight: bold;"> <br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 15%; color: #000000; text-align: center;"></div>
      <div style="text-align: center; color: #000000; font-weight: bold;">(Former Name or Former Address, if Changed Since Last Report)</div>
      <div style="text-align: center; color: #000000; font-weight: bold;"> <br>
      </div>
      <div>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<font style="font-style: italic; color: rgb(0, 0, 0);">see</font> General
        Instruction A.2. below):</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="zf7f1e6a9ff13482ebb914ae3c4594356" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;">&#160;</td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Segoe UI Symbol',sans-serif;">&#9744;</td>
            <td style="vertical-align: top;">
              <div>Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="zeefef314d3b64ae38161b85020d1e022" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;">&#160;</td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Segoe UI Symbol',sans-serif;">&#9744;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="ze0b841ae4df143c6b8be70b7e2599a0d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;">&#160;</td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Segoe UI Symbol',sans-serif;">&#9744;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z948a772c5db1461aa33b81dc3a9eaacd" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;">&#160;</td>
            <td style="width: 18pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Segoe UI Symbol',sans-serif;">&#9744;</td>
            <td style="width: auto; vertical-align: top;">
              <div>Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div>Securities registered pursuant to Section 12(b) of the Act:</div>
      <table cellspacing="0" cellpadding="0" border="0" id="z364654bf01864bb0aba92de64992bd43" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 33%; vertical-align: top; background-color: rgb(255, 255, 255); border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center;">Title of each class</div>
            </td>
            <td style="width: 34%; vertical-align: top; background-color: rgb(255, 255, 255); border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center;">Trading Symbol(s)</div>
            </td>
            <td style="width: 33%; vertical-align: top; background-color: rgb(255, 255, 255); border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center;">Name of each exchange on which registered <br>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 33%; vertical-align: top; background-color: rgb(255, 255, 255); border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center;">Common Stock, par value $0.00033 per share</div>
            </td>
            <td style="width: 34%; vertical-align: top; background-color: rgb(255, 255, 255); border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center;">PDSB</div>
            </td>
            <td style="width: 33%; vertical-align: top; background-color: rgb(255, 255, 255); border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
              <div style="text-align: center;">The Nasdaq Capital Market</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div>Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR <font style="color: rgb(0, 0, 0);">&#167;</font>230.405 of this chapter) or Rule 12b-2 of the Securities
        Exchange Act of 1934 (17 CFR <font style="color: rgb(0, 0, 0);">&#167;</font>240.12b-2 of this chapter).</div>
      <div><br>
      </div>
      <div style="text-align: right;">Emerging growth company &#9746;<font style="font-family: 'Segoe UI Symbol',sans-serif; color: rgb(0, 0, 0);"></font></div>
      <div><br>
      </div>
      <div>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
        Act. &#9746;<font style="font-family: 'Segoe UI Symbol',sans-serif; color: rgb(0, 0, 0);"></font></div>
      <div><font style="font-family: 'Segoe UI Symbol',sans-serif; color: rgb(0, 0, 0);"> <br>
        </font></div>
      <font style="font-family: 'Segoe UI Symbol',sans-serif; color: rgb(0, 0, 0);"> </font>
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" id="z0fcff784a56f442089a1265cb4c4700c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt; vertical-align: top; align: right; color: #000000; font-weight: bold;">Item 8.01</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Other Events.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"><a name="z_Hlk37923265"></a>On May 13, 2020, PDS Biotechnology Corporation (the &#8220;Company&#8221;) issued a press release announcing that it will present an abstract describing the results of the Company&#8217;s
        preclinical studies of PDS0102, at the American Society of Clinical Oncology (ASCO) Virtual Scientific Program being held on May 29-31, 2020. The full text of the press release is attached hereto as Exhibit 99.1 and incorporated herein by
        reference.</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="zf2a1163068634ca09abe353771f065e3" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 72pt; vertical-align: top; align: right; color: #000000; font-weight: bold;">Item 9.01</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Financial Statements and Exhibits.</div>
            </td>
          </tr>

      </table>
      <div style="color: #000000; font-weight: bold;"> <br>
      </div>
      <div style="color: #000000; font-weight: bold;">(d) Exhibits.</div>
      <div style="color: #000000; font-weight: bold;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="z9a314f0db63c4018be7f082fdd3b7558" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

          <tr>
            <td style="width: 8%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Exhibit</div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Number</div>
            </td>
            <td style="width: 2%; vertical-align: top;" colspan="1"><br>
            </td>
            <td style="width: 90%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">
              <div style="color: rgb(0, 0, 0); font-weight: bold;"> <br>
              </div>
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Description</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;">&#160;</td>
            <td style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 90%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 8%; vertical-align: top;">
              <div style="text-align: center; color: rgb(0, 0, 255);"><a href="ex99_1.htm"><u>99.1</u></a></div>
            </td>
            <td style="width: 2%; vertical-align: top;">&#160;</td>
            <td style="width: 90%; vertical-align: top;">
              <div>Press release dated May 13, 2020.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; color: #000000; font-weight: bold;">Signature</div>
      <div style="text-align: center; color: #000000; font-weight: bold;"> <br>
      </div>
      <div style="text-indent: 36pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="zee455dda2ba44eb58313200391e357a9" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 40%; vertical-align: top; background-color: rgb(255, 255, 255);">&#160;</td>
            <td style="width: 10%; vertical-align: top; background-color: rgb(255, 255, 255);"><br>
            </td>
            <td style="width: 50%; vertical-align: top; background-color: rgb(255, 255, 255);">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">PDS BIOTECHNOLOGY CORPORATION</div>
            </td>
          </tr>
          <tr>
            <td style="width: 40%; vertical-align: top; background-color: rgb(255, 255, 255);">&#160;</td>
            <td style="width: 10%; vertical-align: top; background-color: rgb(255, 255, 255);"><br>
            </td>
            <td style="width: 50%; vertical-align: top; background-color: rgb(255, 255, 255);">&#160;</td>
          </tr>
          <tr>
            <td style="width: 40%; vertical-align: top; background-color: rgb(255, 255, 255);">
              <div style="text-align: right;">Date: May 19, 2020</div>
            </td>
            <td style="width: 10%; vertical-align: top; background-color: rgb(255, 255, 255);"><br>
            </td>
            <td style="width: 50%; vertical-align: top; background-color: rgb(255, 255, 255);">
              <div>By: <u><font style="color: rgb(0, 0, 0);">/s/ Frank Bedu-Addo, Ph.D.</font></u></div>
            </td>
          </tr>
          <tr>
            <td style="width: 40%; vertical-align: top; background-color: rgb(255, 255, 255);">&#160;</td>
            <td style="width: 10%; vertical-align: top; background-color: rgb(255, 255, 255);"><br>
            </td>
            <td style="width: 50%; vertical-align: top; background-color: rgb(255, 255, 255);">
              <div>Name: Frank Bedu-Addo, Ph.D.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 40%; vertical-align: top; background-color: rgb(255, 255, 255);">&#160;</td>
            <td style="width: 10%; vertical-align: top; background-color: rgb(255, 255, 255);"><br>
            </td>
            <td style="width: 50%; vertical-align: top; background-color: rgb(255, 255, 255);">
              <div>Title: President and Chief Executive Officer</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
    </div>
    <div> <br>
    </div>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
  </div>
</body>
</html>
[{"type": "8-K", "sequence": "1", "filename": "form8k.htm", "description": "8-K", "secsgml_size_bytes": 19865}]
{"company-data": {"conformed-name": "PDS Biotechnology Corp", "cik": "0001472091", "assigned-sic": "2834", "irs-number": "264231384", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-37568", "film-number": "20891534"}, "business-address": {"street1": "25B VREELAND ROAD", "city": "FLORHAM PARK", "state": "NJ", "zip": "07932", "phone": "800-208-3343"}, "mail-address": {"street1": "25B VREELAND ROAD", "city": "FLORHAM PARK", "state": "NJ", "zip": "07932"}, "former-company": {"former-conformed-name": "Edge Therapeutics, Inc.", "date-changed": "20090911"}}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 13, 2020
PDS BIOTECHNOLOGY CORPORATION
(Exact Name of Registrant as Specified in Charter)
Delaware
001-37568
26-4231384
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
25B Vreeland Road
Florham Park NJ 07932
(Address of Principal Executive Offices, and Zip Code)
(800) 208-3343
Registrant's Telephone Number, Including Area Code
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General
        Instruction A.2. below):
☐
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.00033 per share
PDSB
The Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR
§
230.405 of this chapter) or Rule 12b-2 of the Securities
        Exchange Act of 1934 (17 CFR
§
240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
        Act. ☒
Item 8.01
Other Events.
On May 13, 2020, PDS Biotechnology Corporation (the "Company") issued a press release announcing that it will present an abstract describing the results of the Company's
        preclinical studies of PDS0102, at the American Society of Clinical Oncology (ASCO) Virtual Scientific Program being held on May 29-31, 2020. The full text of the press release is attached hereto as Exhibit 99.1 and incorporated herein by
        reference.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
Number
Description
99.1
Press release dated May 13, 2020.
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PDS BIOTECHNOLOGY CORPORATION
Date: May 19, 2020
By:
/s/ Frank Bedu-Addo, Ph.D.
Name: Frank Bedu-Addo, Ph.D.
Title: President and Chief Executive Officer